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Abstract
Background: To compare the effectiveness of liposomal tobramycin or polymyxin B against Pseudomonas aeruginosa in the
Cystic Fibrosis (CF) sputum and its inhibition by common polyanionic components such as DNA, F-actin, lipopolysaccharides
(LPS), and lipoteichoic acid (LTA).
Methodology: Liposomal formulations were prepared from a mixture of 1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine
(DMPC) or 1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine (DPPC) and Cholesterol (Chol), respectively. Stability of the
formulations in different biological milieus and antibacterial activities compared to conventional forms in the presence of
the aforementioned inhibitory factors or CF sputum were evaluated.
Results: The formulations were stable in all conditions tested with no significant differences compared to the controls.
Inhibition of antibiotic formulations by DNA/F-actin and LPS/LTA was concentration dependent. DNA/F-actin (125 to
1000 mg/L) and LPS/LTA (1 to 1000 mg/L) inhibited conventional tobramycin bioactivity, whereas, liposome-entrapped
tobramycin was inhibited at higher concentrations - DNA/F-actin (500 to 1000 mg/L) and LPS/LTA (100 to 1000 mg/L). Neither
polymyxin B formulation was inactivated by DNA/F-actin, but LPS/LTA (1 to 1000 mg/L) inhibited the drug in conventional
form completely and higher concentrations of the inhibitors (100 to 1000 mg/L) was required to inhibit the liposome-
entrapped polymyxin B. Co-incubation with inhibitory factors (1000 mg/L) increased conventional (16-fold) and liposomal (4-
fold) tobramycin minimum bactericidal concentrations (MBCs), while both polymyxin B formulations were inhibited 64-fold.
Conclusions: Liposome-entrapment reduced antibiotic inhibition up to 100-fold and the CFU of endogenous P. aeruginosa
in sputum by 4-fold compared to the conventional antibiotic, suggesting their potential applications in CF lung infections.
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Introduction
Chronic bronchial infections caused by opportunistic pathogens
in the lower respiratory tract are a major cause of health decline in
the CF population [1]. These recurrent infections are mainly due
to Gram-negative bacteria, with P. aeruginosa being the most
common species isolated [2–4]. Bacterial infections lead to biofilm
formation and host inflammatory responses and the ultimate
resistance to antibacterial therapies results in increased morbidity
and mortality [5–10]. Presently, prophylactic anti-inflammatory
and antibacterial chemotherapy have dramatically improved the
life span of the CF population, albeit pathogenic resistance to
commonly used antibiotics has raised the demand for the
development of novel therapeutic modalities [11–13].
Antibiotics like aminoglycosides and polymyxins have been used
for the treatment of acute or chronic exacerbations in response to
multi-drug resistant (MDR) bacteria, particularly Gram-negative
bacilli such as P. aeruginosa [14–17]. Aminoglycosides including
tobramycin contain broad antibacterial and post-antibiotic effect,
but due to their hydrophilic nature, they are not absorbed and
have adverse effects (i.e. nephrotoxicity, ototoxicity) when
parenterally administered [17–19]. Presently, intravenous admin-
istration of aminoglycosides is widely used by CF clinicians and
limiting the dose to daily administration seems to reduce adverse
effects [20,21]. Polymyxins are cationic polypeptides that bind to
lipopolysaccharide of the Gram-negative bacteria and increase
their membrane permeability and cell death. Cytotoxicity issues
and adaptive resistance by bacterial cell surface alterations have
limited their application to cases where other antibiotics have
failed [22–24].
Clinical studies have shown the success of antibiotics used in
inhalation therapy, alone or in synergism, to combat multi-drug
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resistant P. aeruginosa [25–31]. However, loss of innate immune
response, the emergence of resistant mucoidal strains, and increase
in biofilm production, and the buildup of thick polyanionic sputum
have hampered complete eradication of these infections [7,32–35].
Although an antibiotic may display activity against planktonic
bacteria in vitro, the harsh environment of sputum containing
factors produced by host and the microbes reduce their potential
interactions with the targeted pathogens [36,37]. Clinical
experiments have shown that in the presence of sputum, antibiotic
potency is reduced mainly because of binding to sputum and its
inhibitory components like glycoproteins [e.g. mucin (8–47 mg/
mL)] [38], neutrophil derived DNA (0.6–6.6 mg/mL) [38], and
actin filaments (0.1–5 mg/mL) [39], and bacterial endotoxins such
as LPS and LTA [40–47].
Liposomes are biodegradable delivery vesicles made up of single
or multiple phospholipids in the range of several nanometers to
micrometers [48,49]. It is clear that entrapment of the majority of
antibacterial agents in liposomes tends to enhance bioactivity,
bioavailability, and lower drug toxicity [50–52]. Liposomes may
protect the entrapped agent from aggregation and inactivation
with polyanionic components of the CF sputum, hence increasing
its activity at the site, although the sputum may act as a barrier to
larger liposomes [53–55]. The present study was carried out to
answer the following questions: (i) Are liposome-entrapped
antibiotics stable in the environment of the sputum? (ii) Will the
entrapment within liposomes reduce antibiotic interaction with the
inhibitory factors present in the sputum? (iii) Will liposome-
entrapped antibiotics reduce the number of live bacteria in sputum
more effectively than the free antibiotics?
Our data demonstrate that liposomes are stable in presence of
sputum and inhibitory factors. This data is encouraging as it
displays the ability of lipid vesicles to protect the antibiotics from
inactivation. The study shows that free tobramycin and polymyxin
B, incubated with negatively charged inhibitory factors, is greatly
inhibited compared to liposome-entrapped forms at higher
concentrations. Liposome-entrapped antibiotics display higher
reduction in CFU of endogenous P. aeruginosa in sputum compared
to the free antibiotic suggesting its potency in CF lung infections.
Materials and Methods
F-actin and other chemicals
Human placental DNA, G-actin, Escherichia coli (O111:B4)
lipopolysaccharide (LPS), and Staphylococcus aureus lipoteichoic acid
(LTA) were purchased from Sigma Chemicals Co (St. Louis, MO,
USA). Monomeric G-actin was prepared from an acetone powder
of rabbit skeletal muscle in a non-polymerizing buffer (10 mM
TRIS, pH 7.4, 0.2 mM CaCl2, 0.2 mM ATP, 1 mM Dithiothre-
itol). G-actin was then polymerized to F-actin with the addition of
2 mM MgCl2 and 150 mM KCl and gently shaken for 1 h at
room temperature. Depending on the experiment, DNA, LPS and
LTA were dissolved in double distilled H2O or in cation-adjusted
Mueller-Hinton (CAMH) broth. Synthetic 1,2-Dimyristoyl-sn-
Glycero-3-Phosphocholine (DMPC), Cholesterol (Chol), and 1,2-
Dipalmitoyl-sn-Glycero-3-Phosphocholine (DPPC) were obtained
from Northern Lipids Inc (Burnaby, BC, Canada). Polymyxin B
(Alexis Biochemicals, Burlington, NC, USA), and tobramycin
(Sandoz Laboratories, Boucherville, QC, Canada), were diluted in
Phosphate Buffered Saline solution (PBS: 160 mM NaCl, 10 mM
KH2PO4, pH 7.4).
Organisms
Reference strains P. aeruginosa (ATCC 27853) were purchased
from PML Microbiologicals (Mississauga, ON, Canada). Clinical
isolate strains PA-48912-1, PA-48912-2, and PA-48913 were kindly
obtained from the Clinical Microbiology Laboratory of Memorial
Hospital (Sudbury, ON, Canada) and grown to form biofilm as
described elsewhere [56]. The strains were inoculated onto
CAMH agar plates and incubated for 18 h at 37uC before any
experiments. For any bactericidal experiment involving ATCC
27853, single colonies were suspended to a concentration of 16106
cfu/mL in CAMH broth before addition to 96-well plates.
Preparation and characterization of liposomal antibiotics
Liposome- entrapped tobramycin or polymyxin B was prepared
from a lipid mixture of either DMPC or DPPC and Chol (molar
ratio of 2:1), respectively, by dehydration-rehydration method as
described previously with slight modifications [57,58]. In brief,
lipids were dissolved in chloroform and removed under vacuum at
53uC using a rotary evaporator (Buchi-Rotavapor R205, Brink-
mann, Toronto, ON, Canada). 2 ml of an aqueous solution of
tobramycin or polymyxin B at a concentration of 10 mg/ml were
added to the thin dry lipid film and hand shaken in a warm water
bath for 1 minute. The lipid suspensions were sonicated in a
round-bottom Erlenmeyer flask for 5 minutes (Sonic Dismem-
brator Model 500, Fischer Scientific, USA) while submerged in an
ice-bath. The sonicator was not in direct contact with the liposome
suspension at any time. The suspension was freeze-dried overnight
for preservation and higher entrapment (Labconco model 77540,
USA). At the time of experiment, dehydrated liposomes were
rehydrated in PBS above the phase transition temperature of lipids
(DMPC Tc=23uC; DPPC Tc=41uC), for 2 h and unentrapped
drug was washed off twice by ultracentrifugation at 62000 g. This
step ensures that the unentrapped drug (in the supernatant) is
separated from the liposomal pellet and is aspirated from the
formulation. The liposomal suspensions were diluted at room
temperature and size and polydispersity index was automatically
determined with the use of a NICOMP 270/autodilute Submicron
Particle Sizer according to manufacturer instructions (Santa
Barbara, CA, USA). The content of antibiotic entrapped in
liposomes (after disruption with 0.2% Triton X-100) was measured
by an established method as described previously for tobramycin
and polymyxin B [51,58]. Encapsulation efficiency (EE) was
calculated as follows:
EE %ð Þ~ concentration of antibiotic releasedð Þ=
concentration of initial antibioticð Þ|100%
Stability of liposomes loaded with antibiotics
The stability of antibiotics in the formulations was examined
according to Mugabe et al. [59] at 37uC for 18 h in the presence of
PBS, CAMH broth, supernatant of biofilm forming P. aeruginosa
(PA-48912-1, PA-48912-2, and PA-48913), a combination of DNA,
F-actin, LPS, and LTA at a concentration of 1000 mg/L, and
intact or autoclaved sputum. In experiments involving sputum,
pooled CF sputum was either kept intact and diluted 1:10 (w/v), or
autoclaved for 10 min before mixing with CAMH broth. After
incubation, aliquots of the mixtures were removed and centri-
fuged. Antibiotic presence in the pellet was assayed by the
microbiological assay as described above, and the amount of
antibiotic released from the liposomes was expressed as a
percentage of the total antibiotic concentration at 0 h.
Bacterial killing assays in presence of polyanions
Antibacterial activity of the formulations was measured in the
presence or absence of polyanions found in the CF lung. P.
Liposomal Antibiotics
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aeruginosa (ATCC 27853) was grown on CAMH agar overnight at
37uC. Single colonies were diluted and suspended in CAMH broth
alone or with 2-fold dilutions of LPS, LTA, DNA and F-actin (125
to 1000 mg/L); 2-fold dilutions of DNA and F-actin (125 to
1000 mg/L); and 10-fold dilutions of LPS and LTA (1 to
1000 mg/L). Equal volumes of 100 mL were added to a 96-well
plate to a final concentration of 16106 cfu/mL. To each well,
100 mL of the free or liposome-entrapped antibiotic (0.125–
256 mg/L; final concentration) was added and the plates were
incubated for 3 h at 37uC. The incubation period and concen-
tration chosen were adequate to allow liposome or free antibiotic-
bacteria interaction and eradication. After incubation, the
suspensions were kept cool on ice and bacterial suspensions were
diluted 10–10000 folds in PBS. Wells treated in the absence of
polyanions were plated as is, i.e., without any dilutions. Aliquots
(100 mL) of each dilution were plated on CAMH agar and
incubated overnight at 37uC. The cfu/mL values were then
determined for each of the three independent experiments.
To determine the ability of liposomes to retain their antibiotic
activity, the MBC of the antibiotic formulations were determined
in an 18 h period by a standard microbroth dilution assay in
CAMH broth alone or with a mixture of LPS, LTA, DNA and F-
actin at a fixed concentration of 1000 mg/L. MBC assay was
performed as mentioned above with addition of 2-fold dilutions of
the free or liposomal antibiotic formulations added to the 96-well
plates. The final volume in each well was 200 mL, and PBS or
CAMH alone were used as positive (no antibiotic) and negative (no
bacteria) controls, respectively. Following incubation for 18 h,
aliquots (100 mL) were aspirated from each well and subcultured
on CAMH agar plates overnight. MBC was defined as the lowest
concentration of the antibiotic that resulted in less than 30 cfu live
bacteria/Petri dish.
Expectorated Sputum
The sputum samples were collected by spontaneous expectora-
tion from nine CF patients following informed consent and a
protocol approved by the Research Ethics Committee (Sudbury
Regional Hospital, Sudbury, Ontario, Canada). Patients’ age,
name, treatments and exacerbation records were kept confidential.
Sputum samples colonized with moderate to heavy growth of P.
aeruginosa were pooled and frozen at 280uC in aliquots. To
measure the effects of the formulations on endogenous P.
aeruginosa, aliquots of sputum samples were also stored at 4uC
and used within 24 h of collection. At the time of the experiment,
the sputum samples were diluted 1:10 (w/v) in CAMH broth and
mixed with the antibiotic formulations to achieve concentrations
ranged 1 to 512 mg/L. The mixtures were then incubated for
18 h at 37uC and the cfu/mL of live bacteria was determined
according to the aforementioned protocol. The dilution of the
samples should have affected the viscoelastic properties of the
sputum, and this dilution was only done for easier handling and
measurement of the sputum samples.
Data analysis
All results were expressed as mean6S.E.M. obtained from three
trials. Comparisons between free and liposomal formulations were
made by ANOVA one-way post t-test, and P-values were
considered significant when (*) p,0.05, (**) p,0.01, (***) p,0.001.
Results
Liposome entrapment and sizing
The entrapment efficiency of tobramycin in liposomes com-
posed of DMPC/Chol (35 mg: 10 mg) was 2.4760.19 mg/ml
with a mean size of 293.7641.1 nm, (polydispersity index of
0.7060.12). Liposomes containing polymyxin B in DPPC/Chol
(38 mg: 10 mg) had an entrapment efficiency of 0.460.02 mg/ml,
with a mean size of 445.1649.3 nm (polydispersity index of
0.9160.06).
Stability of liposome-entrapped antibiotics
Liposomal stability and antibiotic leakage in different environ-
ments including CF sputum at 3 or 18 h post-exposure are shown in
Table 1. The release rate of antibiotics in the presence of bacterial
supernatant, polyanionic components, autoclaved or intact sputum
was comparable to PBS buffer or CAMH broth controls.
Effect of DNA, F-actin, LPS, and LTA on bactericidal
activity
To determine the inhibitory effects of DNA, F-actin, LPS, or
LTA on the activity of antibiotics, different concentrations of these
Table 1. Liposome-entrapped antibiotic stability assayed by microbiological assay.
Formulations Conditions Retention at 3 h Retention at 18 h
Liposomal tobramycin PBS buffer 72.763.2% 71.562.6%
CAMH broth 74.662.1% 73.360.5%
Bacterial Supernatant 72.961.6% 74.162.0%
Polyanionic broth 74.362.2% 73.361.8%
Sterile Sputum 72.163.0% 71.461.1%
Intact Sputum 73.861.9% 71.761.4%
Liposomal polymyxin B PBS buffer 67.561.3% 54.961.8%
CAMH broth 65.261.2% 54.761.7%
Bacterial Supernatant 67.562.1% 54.962.7%
Polyanionic broth 69.462.7% 51.362.4%
Sterile Sputum 67.262.6% 53.362.4%
Intact Sputum 65.461.5% 52.361.1%
The stability of the liposomal formulations were examined at 37uC in an 18 h period in the presence of PBS, CAMH broth, supernatant of biofilm forming P. aeruginosa, a
combination of DNA, F-actin, LPS, and LTA, and diluted intact or autoclaved sputum.
doi:10.1371/journal.pone.0005724.t001
Liposomal Antibiotics
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inhibitory factors were co-incubated with the antibiotic formula-
tions during a 3 h pre-incubation first. The free and liposomal
tobramycin at 2 mg/L killed all ATCC 27853 strain within 3 h,
while the liposomal and free polymyxin B eradicated bacteria at
1 mg/L and 2 mg/L, respectively. The bactericidal activity for
both groups of antibiotics in the presence of DNA, F-actin, LPS,
and LTA at the concentrations of 125 to 1000 mg/L is shown in
Figure 1. The activities of free and liposomal antibiotics were
strongly inhibited and liposomal formulations tended to display
lower antibiotic inhibition.
Separately, the inhibition of activity by DNA and F-actin, LPS
and LTA were assessed. When DNA and F-actin were co-
incubated with the tobramycin formulations (Figure 2), free
tobramycin failed to eradicate growth at DNA/F-actin concen-
trations of 125 to 1000 mg/L. Higher concentrations of these
inhibitory factors (500 to 1000 mg/L) however, were required to
hinder the liposomal tobramycin activity. On the other hand,
bactericidal activity of liposomal polymyxin B co-incubated with
DNA/F-actin remained the same as antibacterial activity was not
impaired within 3 h (data not shown). Under the same conditions
discussed above, the effects of bacterial surface components LPS
and LTA on the activity of antibiotics were investigated. Free
tobramycin (Figure 3A) activity was increasingly inhibited at LPS/
LTA concentrations of 1 to 1000 mg/L. While the lower
concentrations (1 to 10 mg/L) did not have any effect, higher
concentrations (100 to 1000 mg/L) of LPS/LTA were able to
Figure 1. Bactericidal activity and inhibition of antibiotics by DNA, F-actin, LPS and LTA. A) Bactericidal concentrations of free
tobramycin (F-TOB) and liposomal tobramycin (L-TOB) were incubated in presence of LPS/LTA (1 to 1000 mg/L). B) Bactericidal concentrations of free
polymyxin B (F-PMB) and liposomal polymyxin B (L-PMB) were incubated in presence of DNA/F-actin/LPS/LTA (125 to 1000 mg/L). Growth controls
are represented at 0 h (empty bar), and 3 h (dark bar). Comparisons between free and liposomal formulations were made by ANOVA one-way post t-
test, and P-values were considered significant when (**) p,0.01, (***) p,0.001.
doi:10.1371/journal.pone.0005724.g001
Liposomal Antibiotics
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inactivate liposomal tobramycin. Polymyxin B formulations
behaved the same as tobramycin in the presence of LPS/LTA,
as indicated in Figure 3B.
Since negatively charged polyanions hindered bactericidal
activity in a short period of time (3 h exposure), their effect on
the MBCs in an 18 h period were also investigated (Table 2).
MBC levels increased 16-fold for free tobramycin (16 mg/L)
compared to 4-fold for its liposomal form (8 mg/L). Free (32 mg/
L) and liposomal polymyxin B (16 mg/L) were inhibited equally
by the polyanions (64-fold increase in MBC).
Antibacterial activity on CF sputum
To test the efficacy of entrapped versus free antibiotics in the CF
sputa, pooled sputum was diluted and incubated with increasing
concentrations of tobramycin and polymyxin B for 18 h. As shown
in Figure 4, bacterial counts were reduced, but neither of the
formulations eradicated endogenous bacteria present in the
sputum. Liposomal tobramycin (128 mg/L; 5.360.1 logs) and
polymyxin B (8 mg/L; 3.860.1 logs) displayed higher bactericidal
activity than free tobramycin (512 mg/L; 5.460.2 logs) and
polymyxin B (32 mg/L; 3.960.1 logs). The sputum itself did not
seem to have any antibacterial activity against endogenous strains
as bacterial counts were increased from 0 h (5.260.1 logs) to 18 h
(7.860.1 logs).
Discussion
Polycationic antibacterial agents, like aminoglycosides and
polymyxins, require self-promoted uptake pathways for entry
and eradication of Gram-negative bacteria [60]. The cationic
antibiotics increase bacterial outer membrane permeability by
displacing magnesium ions and binding to LPS [41,61]. In the
highly ionic CF sputum, however, the high affinity of excreted
polyanionic bacterial endotoxins and glycoproteins from lysed
white blood cells towards cationic antibiotics decreases their
overall interaction with the bacteria in the lungs [46,62].
Liposomes may create a protective environment for antibacterial
agents to minimize such interactions and subsequently maintain a
steady drug concentration in the lungs. Our data on the stability of
the liposomal formulations displays that tobramycin leakage was at
equilibrium after 3 h, while polymyxin B leakage continued up to
half its concentration over 18 h. This suggests that these
nanoparticles are effective in protecting the antibiotics in the CF
sputum in vitro. The stability will ensure a continuous presence of
the antibiotic at the site of infection, and improves antibiotic
bioavailability and biodistribution in vivo [63].
Polyanions like DNA and F-actin have strong affinity for their
multivalent counterions and tend to aggregate (form bundles) in
the presence of cationic antibiotics which block their bioactivity
[40,46,64,65]. Our results demonstrate the capability of liposomes
to reduce the antibiotics’ contact with polyanionic factors in the
sputum and enhance bacteria-antibiotic(s) interactions. The
liposomal formulation protected tobramycin from the inhibitory
actions of DNA/F-actin at low concentrations while neither
polymyxin B formulations were inactivated. Our findings are in
agreement with those reported by Hunt et al. [36] who found a
reduction in tobramycin activity in the presence of DNA (within a
2 h exposure) even when it was pretreated with recombinant
human DNase (rhDNase). Weiner et al. [43] on the other hand,
reported DNA and F-actin aggregation (within a 5 h exposure)
with increasing concentrations of tobramycin, yet bioactivity in a
microbroth dilution assay (within an 18 h exposure) was not
hindered by the presence of either DNA or F-actin. The
inconsistencies among the results of the different studies may be
attributed to factors such as incubation time, co-incubation of
DNA and F-actin, and that DNA/F-actin concentrations were
increased as tobramycin concentration was kept constant. The
protective effect of the liposomes at the lower DNA/F-actin
concentrations may be attributed to the neutral nature of the
phospholipids comprising the liposomes which would not favor
electrostatic interactions between phospholipids with DNA or F-
actin. The lack of effectiveness of tobramycin encapsulated within
Figure 2. Bactericidal activity and inhibition of tobramycin by DNA and F-actin. Bactericidal concentrations of free tobramycin (F-TOB), and
liposomal tobramycin (L-TOB) at 2 mg/L were incubated with P. aeruginosa (ATCC 27853), or in presence of DNA/F-actin (125 to 1000 mg/L). Growth
controls are represented at 0 h (empty bar), and 3 h (dark bar). Comparisons between free and liposomal tobramycin was made by ANOVA one-way
post t-test, and P-values were considered significant when (***) p,0.001.
doi:10.1371/journal.pone.0005724.g002
Liposomal Antibiotics
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liposomes in the presence of the higher concentrations of
polyanionic factors cannot be explained from the results of this
study but it may be possible that a build up of F-actin/DNA
aggregates leads to an increase in viscoelasticity, which ultimately
hinders liposome-bacteria interaction [64,65]. Reports from other
studies have shown that DNA greatly hampers nanosphere
diffusion through sputum and that the rhDNase improves its
diffusion [53,55,66].
With regards to polymyxin B, reports from studies have shown
G-actin polymerization in the presence of polymyxin B [37] and
DNA and polymyxin B precipitation in vitro [67]. In our studies,
there was no loss of bioactivity when DNA, F-actin, or both were
incubated with polymyxin B (data not shown). The observation of
consistent bacterial killing by polymyxin B can be attributed to the
ability of the antibiotic to resist bundle formation, and having a
higher affinity for polyanionic LPS of the bacterial outer wall than
DNA or F-actin. Weiner et al. [43] reported no aggregation or
reduction of bioactivity between colymycin, an anionic colistin
form, and DNA or F-actin. However, the absence of aggregation
may be due to the similar negative charges of the antibiotic and
DNA or F-actin.
The binding of free bacterial surface components (e.g. LPS and
LTA) to polycationic antibiotics like polymyxin B may be
beneficial to the host in terms of suppressing inflammation
however it will compromise the antibacterial effect of the
antibiotic. Tobramycin and polymyxin B tend to interact with
the bacterial lipid membranes as indicated by the results of this
study where the bioactivity of both antibiotics was reduced when
Figure 3. Bactericidal activity and inhibition of antibiotics by LPS and LTA. A) Bactericidal concentrations of free tobramycin (F-TOB) and
liposomal tobramycin (L-TOB) were incubated in presence of LPS/LTA (1 to 1000 mg/L). B) Bactericidal concentrations of free polymyxin B (F-PMB)
and liposomal polymyxin B (L-PMB) were incubated in presence of LPS/LTA (1 to 1000 mg/L). Growth controls are represented at 0 h (empty bar), and
3 h (dark bar). Comparisons between free and liposomal formulations were made by ANOVA one-way post t-test, and P-values were considered
significant when (***) p,0.001.
doi:10.1371/journal.pone.0005724.g003
Liposomal Antibiotics
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co-incubated with LPS/LTA. However, the bioactivity of the
antibiotics within the liposomes fared better (Figure 3) although
inhibited at the higher LPS/LTA concentrations. The mechanism
of inactivation of liposomal antibiotics by the higher polyanionic
LPS/LTA levels cannot be attributed to the release of antibiotics
from liposomes and subsequent inactivation because results from
the liposomal stability studies (Table 1) showed that the lipid
bilayers were not lysed. This is consistent with results from another
study reported by Davies et al. [68] where divalent anions
entrapped in negative or positive charged liposomes when
incubated with LPS were not significantly leaked from the
liposomes which were not lysed. It is possible then that the higher
concentrations of LPS/LTA may contribute to the stabilization of
the liposomes, reduce antibiotic release, and thus prevent the
leakage of the antibiotics leading to reduction of their interaction
with bacteria.
If the lipid bilayers of liposomes can decrease antibiotic
interactions with the polyanionic components found in CF lungs
and reduce bacterial growth within a 3 h period much more
strongly than free antibiotics, its long term advantage and presence
in an 18 h period would be advantageous (Table 2). Unfortunate-
ly, prolonged contact between polyanions and the formulations
greatly increased the free and liposomal polymyxin B bactericidal
concentrations, with liposomal tobramycin exhibiting better
activity than free tobramycin. The dissimilar inhibitory effects
on tobramycin and polymyxin B may be attributed to differences
in their mechanisms of action, as tobramycin, a polar drug can
enter the cell while polymyxin B a lipophilic agent interacts with
LPS on the cellular surface. The interaction of polymyxin B with
cell surface LPS, in addition to the interaction with the polyanions
might leads to competition at the LPS binding site of bacteria,
ultimately reducing antibiotic binding.
In light of the higher bactericidal activities and lower
inactivation of liposomal antibiotics in the presence of polyanionic
components in vitro, we sought to compare the bactericidal activity
of these formulations against endogenous P. aeruginosa in CF sputa
to that of the free drug. As shown in Figure 4, the antibacterial
activity of liposomal antibiotics was more effective than the free
antibiotics by 4-fold, although due to a large microbial population
in the CF sputum, neither of the formulations fully eradicated
bacterial growth. While liposomal tobramycin (128 mg/L) re-
duced growth, liposomal polymyxin B (8 mg/L) fell into clinically
acceptable levels. The high concentrations of antibiotics, tobra-
mycin in particular, required to lower growth, may be primarily
due to samples containing antibiotic resistant strains, or the
sputum and its contents impeding antibiotic effects by acting as a
physical barrier or inhibitor. Several studies have dealt with the
inhibitory properties of sputum on antibiotics [34,42,69] while
there have been a limited number of studies focused on liposomal
penetration and interaction with sputum [53–55,70]. The majority
of these studies have focused on gene therapy and their transport
across the sputum, but a recent work by Meers et al. [54] showed
the ability of labeled neutral liposomes to penetrate sputum, and
furthermore, aminoglycosidic amikacin-entrapped liposomes were
more efficacious than free amikacin in reducing bacterial growth
in a rat P. aeruginosa infection model. In our study, due to issues of
confidentiality, we did not have access as to the clinical status of
the patients or their pathology laboratory reports. Nevertheless,
delivery of antibiotics via a liposomal system enhanced their
antibacterial activity in sputum.
Although liposome entrapment of antibiotics and their
increased efficacy is not a novel finding, neutral liposome-
entrapped antibiotics tended to be more bactericidal in sputum
and in the presence of sputum components when compared to free
Table 2. Minimum Bactericidal Concentrations.
Formulations MBC (mg/L)
CAMH broth Inhibitory factors
Free tobramycin 1 16
Lipo tobramycin 2 8
Free polymyxin B 0.5 32
Lipo polymyxin B 0.25 16
Bactericidal activity of free and liposomal formulations against susceptible P.
aeruginosa ATCC 27853 strain was carried out in broth alone or in presence of
DNA/F-actin/LPS/LTA at a final concentration of 1000 mg/L.
doi:10.1371/journal.pone.0005724.t002
Figure 4. CF Sputum treatment with various antibiotic formulations. CFU counts were made after incubation of diluted CF sputum (1:10 w/
v) in PBS with two-fold dilutions of free tobramycin at 512 mg/L (F-TOB), liposomal tobramycin at 128 mg/L (L-TOB), free polymyxin B at 32 mg/L (F-
PMB), and liposomal polymyxin B at 8 mg/L (L-PMB). Growth controls are represented at 0 h (empty bar), and 18 h (dark bar).
doi:10.1371/journal.pone.0005724.g004
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antibiotics, but with reduced efficacies over a longer period of time
in vitro (18 h exposure). This decrease in efficacy appears to be the
result of pro-longed interactions of the liposomes with the
polyanionic factors found in sputum. As prophylactic and anti-
inflammatory treatments are improving the lung function of CF
patients, reduction in neutrophil inflammatory response and
bacterial infections may reduce its lysis and the presence of
charged macromolecules which tend to inactivate cationic
antibiotics. As novel approaches proceed towards a cure for CF,
research must also be directed on strategies that obstruct the
presence and/or action of inhibitory factors associated with the
disease. Future work in our laboratory will tend to focus on
disruption of these negatively charged factors for increased
liposomal penetration.
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